Table 3 Comparison of HRCT findings between patients with and without anti-CADM-antibody
MDA-5 positive | MDA-5 negative | p value | |
|---|---|---|---|
(n = 10) | (n = 6) | ||
Distribution | |||
Upper lobe dominant | 1 (10 %) | 0 | 1.00 |
Lower lobe dominant | 9 (90 %) | 6 (100 %) | 1.00 |
Peribronchovascular | 2 (20 %) | 4 (67 %) | 0.118 |
Subpleural | 8 (80 %) | 2 (33 %) | 0.118 |
Main findings | |||
Consolidation | 1 (10 %) | 5 (83 %) | 0.00762 |
Ground glass opacity | 5 (50 %) | 0 | 0.0934 |
Reticulation | 1 (10 %) | 0 | 1.00 |
Irregular linear opacity | 3 (30 %) | 1 (17 %) | 1.00 |
Additional findings | |||
Traction bronchiectasis | 5 (50 %) | 4 (67 %) | 0.633 |
Cyst | 0 | 1 (17 %) | 0.375 |
Subpleural curve linear shadow | 4 (40 %) | 3 (50 %) | 1.00 |
Thickening of interlobular septa | 2 (20 %) | 2 (33 %) | 0.604 |
Emphysema | 1 (10 %) | 1 (17 %) | 1.00 |
Volume loss | 9 (90 %) | 5 (83 %) | 1.00 |